During the recent session, ATAI Life Sciences N.V (NASDAQ:ATAI)’s traded shares were 0.68 million, with the beta value of the company hitting 0.78. At the last check today, the stock’s price was $1.07, reflecting an intraday loss of -4.54% or -$0.05. The 52-week high for the ATAI share is $2.85, that puts it down -166.36 from that peak though still a striking 4.67% gain since the share price plummeted to a 52-week low of $1.02. The company’s market capitalization is $179.39M, and the average intraday trading volume over the past 10 days was 0.76 million shares, and the average trade volume was 611.01K shares over the past three months.

ATAI Life Sciences N.V (ATAI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ATAI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.

ATAI Life Sciences N.V (NASDAQ:ATAI) trade information

ATAI Life Sciences N.V (ATAI) registered a -4.54% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.54% in intraday trading to $1.07, hitting a weekly high. The stock’s 5-day price performance is -6.22%, and it has moved by -1.92% in 30 days. Based on these gigs, the overall price performance for the year is -13.08%. The short interest in ATAI Life Sciences N.V (NASDAQ:ATAI) is 9.59 million shares and it means that shorts have 18.44 day(s) to cover.

The consensus price target of analysts on Wall Street is $6, which implies an increase of 82.17% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, ATAI is trading at a discount of -460.75% off the target high and -460.75% off the low.

ATAI Life Sciences N.V (ATAI) estimates and forecasts

Statistics show that ATAI Life Sciences N.V has underperformed its competitors in share price, compared to the industry in which it operates. ATAI Life Sciences N.V (ATAI) shares have gone down -49.81% during the last six months, with a year-to-date growth rate less than the industry average at -212.00% against 17.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -164.00% this quarter and then drop -33.30% in the quarter after that. In the rating firms’ projections, revenue will increase 43.30% compared to the previous financial year.

Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 370k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 87k and 18k respectively.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 44.19%. While earnings are projected to return -222.86% in 2024.

ATAI Dividends

ATAI Life Sciences N.V is due to release its next quarterly earnings on 2024-Nov-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders

ATAI Life Sciences N.V insiders own 9.99% of total outstanding shares while institutional holders control 27.04%, with the float percentage being 30.04%. WALLEYE CAPITAL LLC is the largest shareholder of the company, while 114.0 institutions own stock in it. As of 2024-06-30, the company held over 2.76 million shares (or 1.7388% of all shares), a total value of $3.67 million in shares.

The next largest institutional holding, with 2.72 million shares, is of MORGAN STANLEY’s that is approximately 1.7111% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.62 million.